Sen. Amy Klobuchar, a fierce critic of Amazon’s market energy, is urging the Federal Commerce Fee (FTC) to research the e-commerce big’s proposed $3.9 billion acquisition of major well being care supplier One Medical.
The Minnesota Democrat, chair of the Senate Judiciary antitrust subcommittee, requested the FTC in a letter Thursday to research the deal over issues she stated it raises about anti-competitive habits within the pharmaceutical business and delicate information it will permit the corporate to build up.
“This proposed transaction raises questions on potential anticompetitive results associated to the pharmacy providers enterprise Amazon already owns and about preferencing distributors who supply different providers by means of Amazon,” Klobuchar wrote.
“I additionally ask that the FTC think about the position of knowledge, together with as a possible barrier to entry, provided that this proposed deal might outcome within the accumulation of extremely delicate private well being information within the palms of an already data-intensive firm,” she added.
An Amazon spokesperson didn’t instantly reply to a request for remark.
The American Financial Liberties Challenge has pushed for regulators to dam Amazon’s One Medical Acquisition, calling it harmful.
“Permitting Amazon to manage the well being care information for an additional 700,000+ people is terrifying,” Krista Brown, a senior coverage analyst on the American Financial Liberties Challenge, stated in an announcement.
Brown stated the deal would “entrench Amazon’s rising presence” within the well being care business in a approach that undermines competitors and poses “critical dangers” to sufferers’ delicate information.
Klobuchar has been an outspoken critic of the market energy of Amazon and different tech giants. She’s the lead sponsor on a bipartisan antitrust reform invoice, the American Innovation and On-line Alternative Act, that goals to maintain business giants, together with Amazon, from preferencing their very own merchandise over their rivals.
The invoice superior out of the Judiciary Committee earlier this yr with bipartisan help, however it has not been referred to as for a full Senate vote.